1 of 54

Dapsone-induced methemoglobinemia

Hope Vertrice Askew, PharmD

PGY-1 Pharmacy Resident

Parkland Health

March 9th, 2022

2 of 54

Objectives

Describe the pathophysiology of dapsone-induced methemoglobinemia

Understand and interpret lab values and imaging associated with methemoglobinemia

Identify common clinical presentations and symptoms associated with methemoglobinemia

Compare the pharmacologic treatment options for methemoglobinemia

Design a treatment plan for a patient with Dapsone-induced methemoglobinemia

2

3 of 54

Our Patient

IP is a 30-year-old Hispanic female, who presented to Parkland’s ED on 10/29/21 for anorexia, abdominal pain, and diarrhea x 2 weeks with no relief from OTC’s.

3

4 of 54

Patient: IP

HPI: Recently admitted to Parkland one month ago where she was started on PJP prophylaxis due to anticipated chronic steroid dependence (newly diagnosed lupus nephritis). After admission, her SpO2 began to decline rapidly (94% to 84%) now requiring 6L nasal canula with no explained insinuating cause.

Social History:

    • Never smoked
    • No hx of alcohol use
    • No hx of drug use
    • Jehovah's Witnesses – no blood transfusions

PMH:

    • Lupus nephritis (new diagnosis 9/2021)
    • CKD (baseline SCr: ~3.2)
    • HTN
    • HLD
    • Prediabetes (A1c 5.7%)
    • Normocytic Anemia (baseline Hgb ~9 to 11)

Family History:

    • None concerning for CKD/ESRD/ immune mediated disorders/ recent viral syndrome
    • Mother: DM and HTN

4

5 of 54

Medications Prior to Admission

Medication

Dose/Frequency

Notes:

Acyclovir

400 mg twice daily

CMV/antiviral prophylaxis

Amlodipine

10 mg daily

​

Atorvastatin

40 mg daily

Chol = 517, LDL = 336, TG = 665

Carvedilol

25 mg twice daily

​

Dapsone

100 mg daily

PJP prophylaxis

Ergocalciferol

50,000 units weekly

​

Lisinopril

10 mg daily

​

Mycophenolate

1,000 mg twice daily

lupus nephritis

Pantoprazole

20 mg daily

GI prophylaxis due to high dose steroid

Prednisone

60 mg daily

No taper planned, f/u renal outpatient

OTC: acetaminophen, ibuprofen, aspirin - as needed for pain unknown dose or frequency

Allergies: diclofenac - rash

5

6 of 54

Review of Systems and Physical Exam (10/29/21)

6

General

Well-developed and well-nourished

No fever or chills

HEENT*

No headaches or sore throat

No vision changes or eye pain

Head, ears, eyes, nose, and mouth physical presence normal

Respiratory

No cough or dyspnea

No respiratory distress, breath sounds clear and normal

No hemoptysis

Cardiovascular

Regular rhythm and heart sounds

No lower extremity edema

*HEENT: head, ears, eyes, nose, throat

7 of 54

Review of System and Physical Exam (10/29/21)

Skin

No rash or itching

Warm and dry

No cyanosis or edema

Skin intact with no cuts, bruises, ulcers, or abrasions

Gastrointestinal

Nausea, vomiting

Abdominal pain (no distention) and diarrhea

No melena/hematochezia or hematemesis

Genitourinary

No bleeding

Neurological

No dizziness or weakness

Symmetric facial/extremity movement, normal ambulation

A&O x 4

Psychiatric/Behavioral

Mood and affect normal

7

8 of 54

Objective Findings - Upon Admission (10/29/21)

8

    • BP: 118/75
    • Pulse: 64
    • Temperature: 98.3°F
    • Respiratory Rate: 16 bpm
    • SpO2: 94%
    • Height/weight: 4’11ā€ / 116 Ibs (BMI 23.3)

Vitals

    • C.diff and stool cx: negative
    • HIV and CMV IgM: negative
    • Hepatitis Panel: normal
    • G6PD: normal
    • Pregnancy Test: negative (prior to dapsone start 9/22/21)
    • COVID-19: negative (vaccinated)
    • Chest X-Ray (11/2/21): normal
    • Peripheral Blood Smear: bite cells and blister cells

Labs and Imaging

G6PD deficiency, oxidative stress & toxic metabolite in RBC’s are increased

​

Leads to the iron and bond breaking – oxidative drug-induced hemolytic anemia

​

When the RBC passes through the spleen, macrophages take a ā€œbiteā€

Bite Cells

8

9 of 54

Objective - Labs (10/29/21 🔪 11/2/21)

9

CBC

BMP

Other

WBC

7.93 🔪 5.98

Na

135

Iron

442 (H)

RBC

1.87

K

4.4

Pct Sat

79 (H)

Hgb

6.5 (L) 🔪 4.8

CO2

14 (L)

Ferritin

319 (H)

Hct

20.0 (L)

BUN

103 (H) 🔪 74 (H)

B12

462

MCV

107 (H) 🔪 107

SCr

2.85 (H) 🔪 2.45 (H)

MetHb

21.1 (H)

PLT

208 🔪 190

eGFR

19 (L)

Haptoglobin

<5

Neutro ABS

7.14 (H)

​

​

Lactate Dehydrogenase

401 (H)

Lymph ABS

0.35 (L)

​

​

AST

20

EOS Ab

<0.03 (L)

​

​

ALT

14

Hgb: hemoglobin

MetHb: methemoglobin

DAT: negative (11/4/21); Reticulocyte count: 4.7 (11/2/21)

9

10 of 54

Drug-Induced ļæ½Methemoglobinemia

Pathophysiology and Epidemiology

​

11 of 54

What is methemoglobinemia?

In normal hemoglobin, iron is in it’s ferrous (Fe2+) state 🔪 allows for binding of oxygen (O2) in lungs that can be further released to the tissues

Methemoglobin is a form of hemoglobin that has been altered due to oxidization

Condition where ferrous iron’s (Fe2+) heme group becomes oxidized to ferric iron (Fe3+)

Results in functional anemia, due to oxygen unable to effectively be delivered to hypoxic tissues despite the rich O2 environment

Am J Physiol. 1942;137:56

Drug Saf. 1996;14(6):394

Williams Hematology, 10e. McGraw Hill; 2021

11

12 of 54

What is methemoglobinemia?

Oxidation (removing e-) is NOT the same as oxygenation (O2 binding)

Ferric heme of methemoglobin does NOT bind to O2

Consequences depend on if MetHb is chronically or acutely increased

Am J Physiol. 1942;137:56

Drug Saf. 1996;14(6):394

Post TW, ed. UpToDate.

Williams Hematology, 10e. McGraw Hill; 2021

12

Influences other Hgb molecules to have decrease O2 affinity

​

Results, in the inability of O2 binding 🔪 left-shifts of O2 curve = anemia

13 of 54

What is methemoglobinemia?

  • Classifications of methemoglobinemia:
    1. Congenital (chronic)
      • Infants and children 🔪 increased levels associated w/ functional anemia develops due to compensatory erythrocytosis 🔪 typically asymptomatic except cyanosis (cosmetic concern)
    2. Acquired (acute)
      • Due to toxicity of methemoglobin 🔪 severe illness and mortality from severe hypoxia despite supplemental O2

Treatment is very specific and usually not available in an EMS setting

Am J Physiol. 1942;137:56

Drug Saf. 1996;14(6):394

Williams Hematology, 10e. McGraw Hill; 2021

13

Quick Reminder: IP’s

MetHb = 21

  • Even acute changes in the O2 carrying capacity can cause important clinical consequences:
    • Cyanosis (occurs when MetHb levels >8-12%) 🔪 if no hx of anemia or cardiovascular compromise maybe asymptomatic until MetHb >15%

​

14 of 54

Most common causes for ļæ½drug-induced methemoglobinemia

ā€œcainesā€

lidocaine, xylocaine, benzocaine, cocaine

Antimalaria Agents

chloroquine, primaquine, hydroxychloroquine

Nitrates and Nitrites

​

Sulfa Medications

trimethoprim/sulfamethoxazole, furosemide, dapsone

Am J Physiol. 1942;137:56

Drug Saf. 1996;14(6):394

N Engl J Med. 1968;279(21):1127-1131

Arch Intern Med. 2007;167(18)

Cochrane Database Syst Rev. 2014

Williams Hematology, 10e. McGraw Hill; 2021s

14

15 of 54

How dapsone causes methemoglobinemia

15

Dapsone is metabolized and bioactivated in the liver to a potent metabolite, hydroxylamine

Dapsone hydroxylamine (metabolite) rapidly depletes erythrocyte glutathione levels 🔪 increasing oxidation rate of hemoglobin to methemoglobin… G6PD Deficiency

​

Methemoglobin is unable to bind oxygen 🔪 decreased oxygen delivery to tissues 🔪 cyanosis, dyspnea and tachycardia

Patients at highest risk for dapsone-induced methemoglobinemia include anemic, underlying cardiovascular conditions, chronic respiratory dysfunctions, and elderly patients

Dapsone’s effect may be a dose related. Where elevated dapsone levels occur in renal dysfunction and/or other medications that utilize P-450 cytochrome enzyme pathway

Br J Dermatol. 1993;129(5):507-513.

J Neurooncol (2009) 94:149–152

Medicine (Baltimore). 2004;83(5):265.Ā 

15

16 of 54

PJP Prophylaxis

  • Pneumocystis jiroveciiĀ pneumonia (PJP), formerly calledĀ Pneumocystis cariniiĀ pneumonia (PCP)
  • Most common opportunistic respiratory infection in immunocompromised people
  • No guidelines for PJP ppx in patients with rheumatologic diseases
  • But commonly used if patients are on high dose immunosuppressive therapy
    • High dose immunosuppression = Prednisone > 20 mg daily for >1 month plus cytotoxic medication
  • Prophylactic Options:
    1. Trimethoprim-sulfamethoxazole
      • 1 double strength tablet daily
      • Treatment of choice
      • Renal dose adjustments (CrCl < 30 mL/min), sulfa-allergies
    2. Atovaquone
      • Restriction: documented allergy/intolerance to other agents used in PCP
    3. Dapsone
      • 100 mg daily
      • Cheaper compared to atovaquone
      • preferred if no concern for hematologic toxicity (G6PD Deficiencies)
      • No renal dose adjustments

Infect Dis Clin North Am. 2010;24(1):107-138.

16

17 of 54

18 of 54

Drug-Induced ļæ½Methemoglobinemia

Clinical Presentation and Diagnosis

​

19 of 54

Clinical Presentation

after exposure to substance that causes MetHb formation

Acute development of hypoxia

dark red, chocolate in color, does not resolve upon oxygenation

Discoloration of the blood

coma, seizures

fatigue, irritability

headache, lightheadedness

Neurologic deterioration

+/- pale, grayish blue colored skin, lips, and nail beds despite normal arterial oxygen pressure (PaO2)

Mild cyanosis

Despite supplemental O2 requirements

Normal arterial oxygen pressure (PaO2)

www.uptodate.com. Methemoglobinemia.

19

Quick Reminder: IP’s

MetHb = 21

20 of 54

When to Suspect…

Unexplained cyanosis or hypoxia w/ pulse oximetry ~85% (despite supplemental O2)

Prior history of methemoglobinemia

Positive family hx for methemoglobinemia

Positive genetic testing for variant in one of the methemoglobinemia genes

Known exposure to methemoglobinemia-inducing substance

Respiratory or neurologic symptoms (shock if severe)

Dark red or brown blood that does not turn red with oxygenation

http://www.emdocs.net/tox-card-methemoglobinemia/

20

21 of 54

Diagnosis + Work-Up

21

Rule Out Genetic Causes

(include 1st degree relatives)

Initiate Treatment

(if indicated per methemoglobin level and severity of symptoms)

Complete Blood Count (CBC)

(would expect to see normal Hgb 🔪 no compensatory erythrocytosis b/c not enough time to develop)

G6PD Deficiency

(help determine which therapy to use & if pt had dapsone exposure, may see Heinz bodies in blood smear)

Methemoglobin levels > 5%

(to confirm diagnosis & determine if treatment is required)

Eliminate Exposure

(if applicable)

21

22 of 54

Do Use

Do NOT Use

  • Blood gas measurement
    • arterial or venous
  • Co-oximetry
    • pulse oximeter that uses light wavelengths and detects absorption of methemoglobin
  • Evelyn Malloy Assay
    • considered most accurate
    • rarely used due to send out lab
  • Routine pulse oximetry
    • can not distinguish between methemoglobin, normal oxy-hemoglobin and deoxy-hemoglobin)
  • PaO2 and SaO2 blood glass levels
    • O2 levels may be normal or falsely high although pt has severe methemoglobinemia

How to Properly Detect Methemoglobin

J Anaesthesiol Clin Pharmacol. 2013;29(1):139

22

23 of 54

Differential Diagnosis

Carbon Monoxide Poisoning

    • Produces carboxyhemoglobin instead of methemoglobin
    • CANNOT be determined using a pulse oximetry

​

www.uptodate.com. Methemoglobinemia.

23

IP’s Levels on 11/2:

MetHb = 21

CarboxyHb = 0.0

24 of 54

Drug-Induced ļæ½Methemoglobinemia

Treatment Options

25 of 54

Treatment Options – Overview

Initial treatment if MetHb >30% or symptoms other than headache and/or lethargy:

  • Methylene blue (if not G6PD deficient) vs. ascorbic acid
  • Stop the eliciting medication
  • Supportive care
    • IV access, hydration for hypotension, vent support for resp. compromise, tx for neurologic complications (ie. antiseizure medication)
  • Exchange transfusion and/or hyperbaric O2
    • No controlled trials to support use
    • CDC recommends use using if exposed to aniline dye with no improvement from methylene blue use
  • Persistent methemoglobinemia
    • Blood transfusion may be used, especially if anemic

Asymptomatic or mildly symptomatic with MetHb <30% with or without cyanosis

    • Methylene blue or ascorbic acid is NOT required unless severe symptoms develop during observation
    • Continue to follow the patient without therapy after the offending drug or agent is withdrawn

​

J Med Case Rep. 2012;6:290. Epub 2012 Sep 11

25

26 of 54

1st Line - Treatment Option

Methylene Blue (MB)

​

FDA Approved IndicationsĀ 

  • Drug of choice for acute toxic methemoglobinemia with MetHb levels >30%
  • Symptomatic methemoglobinemia with MetHb levels between 20-30%, especially those with pulmonary or cardiac comorbidities
  • Used cosmetically to decrease cyanosis in congenital (chronic) methemoglobinemia due to cytochrome b5 reductase (Cyb5R) deficiency

​

​

Methylene Blue [prescribing information].

26

27 of 54

1st Line - Treatment Option

Methylene Blue (MB)

​

Pharmacokinetics

  • Onset of action: 30-60 minutes
  • Absorption: 50-97%
  • Metabolism: 1st pass metabolism, peripherally reduced to leukomethylene blue
  • Half-life elimination: 5-6.5 hours
  • Time to peak: 1-2 hours (oral); 30 minutes (IV)
  • Excretion: ~33% of leukomethylene blue metabolite via bile, feces, urine

​

J Pharm Sci, 1972, 61(7):1086-90.

27

28 of 54

1st Line - Treatment Option

J Pharm Sci, 1972, 61(7):1086-90.

27

Methylene Blue (MB)

29 of 54

1st Line - Treatment Option

Methylene Blue (MB)

ContraindicationsĀ 

  • G6PD deficiency: can precipitate hemolysis and/or paradoxical case of methemoglobinemia
    • If G6PD status is unknown w/ concern for G6PD deficiency (ie. Mediterranean, Puerto Rican, African, or Southeast Asian) start low dose and monitor closely
  • Black Box Warning - Individuals receiving serotonergicĀ agents (SSRI, SNRI, MAOI’s): can precipitate serotonin syndrome (potentially life-threatening) due to acting as a potent monoamine oxidase inhibitor (MAOI)

Ann Intern Med. 1971;75(1):83

Methylene Blue [prescribing information].

28

30 of 54

1st Line - Treatment Option

Methylene Blue (MB)

Ann Intern Med. 1971;75(1):83

Methylene Blue [prescribing information].

28

31 of 54

1st Line - Treatment Option

Methylene Blue (MB)

Recommended Dosing

  • SevereĀ (MetHb >30% with toxic symptoms): 1-2 mg/kg IV (max: 100mg), given over 5 min
    • Optimal dose is unknown
    • May repeat in 1 hour if MetHb level remains high (eg, >30%) and/or if MetHb continues to increase
    • Avoid giving >2 doses (>7 mg/kg) due to the possibility of causing hemolysis, even in individuals who do not have G6PD deficiency 🔪 switch to alternative therapy
  • MildĀ (toxic exposure with less-concerning symptoms and MetHb 20-30%): start with 1 mg/kg IV

Dose Adjustments

  • Kidney Dysfunction: eGFR <60 = 1mg/kg 1x dose (if MetHb <30% and eGFR <60, consider alt therapy)
  • Hepatic Impairment: extensively metabolized by liver, monitor for AEs/ toxicities

​

West J Med. 1984;140(2):282

Methylene Blue [prescribing information].

29

32 of 54

1st Line - Treatment Option

Methylene Blue (MB)

Monitoring ParametersĀ 

  • Arterial Blood Gas
  • Cardiac monitoring
  • CBC
  • Methemoglobin levels
  • Renal function
  • s/sx’s of methemoglobinemia (pallor, cyanosis, confusion, dizzy, dyspnea, tachycardia, transcutaneous O2 saturation)

Methylene Blue [prescribing information].

30

33 of 54

1st Line - Treatment Option

Methylene Blue (MB)

Expected response

  • Rapid clinical improvement with decreased MetHb levels by < 10% within 30-60 minutes
    • If improved rapidly (as most do) and cyanosis subsides 🔪 no need to recheck methemoglobin (accuracy of MetHb measurement is impaired by MB interference)
    • If cyanosis returns and symptoms of hypoxia recur (likely due to continuous presence of offending agent) 🔪 repeat dose of MB
  • If no rapid Improvement occurs 🔪 confirm original diagnosis and consider other interventions like exchange transfusion or hyperbaric oxygen

​

Co-oximetry detects MB as MetHb 🔪 cannot use to follow response of MetHb levels with MB treatment

Ā Br J Clin Pharmacol. 1992;34(3):244-249.

Methylene Blue [prescribing information].

31

34 of 54

1st Line - Treatment Option Alternative

Ascorbic Acid (Vitamin C)

IndicationsĀ 

  • Severe or symptomatic methemoglobinemia when MB is unavailable or contraindicated (eg, due to suspected or proven G6PD deficiency or if someone is receiving an SSRI)
  • Cosmetically used to decrease cyanosis in patients with congenital (chronic) methemoglobinemia due to cytochrome b5 reductase (Cyb5R) deficiency

​

Ascor (ascorbic acid) [prescribing information].

32

35 of 54

1st Line - Treatment Option Alternative

Ascorbic Acid (Vitamin C)

Dosing

  • SevereĀ (MetHb >30% with toxic symptoms): 1-10 grams every 6 hours until methemoglobin levels return to normal

Dose Adjustment:

  • Kidney Dysfunction: no dose adjustment required but recommend to use cautiously due to increased risk of developing Ā oxalate nephropathy

​

  • ESRD/HD: 60-100 mg daily

​

  • Hepatic Dysfunction: no adjustment required, is a water-soluble vitamin

Am J Emerg Med. 2014 Jun;32(6):684.e1-3. Epub 2013 Nov 26.

33

36 of 54

1st Line - Treatment Option Alternative

Ascorbic Acid (Vitamin C)

Expected response

  • In severe methemoglobinemia, improvement takes 1-3 days depending on initial MetHb level

​

Adverse effects

  • Kidney stones (oxalate crystal deposition) & kidney failure if taking extremely high doses of ascorbic acid over prolonged periods of time

​

Monitoring Parameters

  • Renal function
  • Hemoglobin/ blood counts (especially if G6PD deficient)

Ascor (ascorbic acid) [prescribing information]

34

37 of 54

Other Treatment Options and Recommendations

Cimetidine

  • May be effective in increasing patient tolerance to dapsone due to being a metabolic inhibitor
  • Chronically lowers methemoglobin level by ~25%
  • Works slowly, do NOT use for management of acute symptomatic methemoglobinemia arising from the use of dapsone

Avoidance of Precipitating ExposuresĀ 

  • Avoid oxidant substances that can precipitate and any individual with a history of congenital or acquired methemoglobinemia

Genetic Testing

  • 1st degree relatives (parents, siblings, and children) possibility to be heterozygous. Recommend to be tested and/or to avoid these substances

​

37

Coleman MD, Rhodes LE, Scott AK, et al.

Indian J Crit Care Med. 2014;18(4):253.

35

38 of 54

Summary: Treatment Options – MOA

Indian J Drugs Dermatol 2018;4:79-81

Toxic Metabolite

36

39 of 54

Drug-Induced ļæ½Methemoglobinemia

Evidence Based Treatment Recommendations

40 of 54

Literature Overview

  • MB and ascorbic acid have not been directly compared in RCT’s for their efficacy
  • Evidence only comes from a small number of case reports
  • MB preferred due to rapid onset and improvement with treatment especially in those who have MetHb >30%
  • Ascorbic acid requires multiples doses and takes 24+ hrs to lower MetHb levels

38

41 of 54

Case Studies

  • 50-year-old male with s/sx of severe methemoglobinemia
    • MetHb of 81.5%
    • Given MB 140 mg IV x1 dose
    • Gradually became more responsive and discharged with no neurologic deficit 3 days later
  • Decreasing dapsone methemoglobinemia occurrence
    • When given cimetidine prophylactically, may improve dapsone tolerance
    • Cimetidine 1.6 g daily concurrently for 3 months
  • 84-year-old woman with dapsone-induced severe methemoglobinemia
    • Ascorbic acid 10 g every 6 hours until MetHb fell below 10%
    • Reduced MetHb levels with no adverse effectsļæ½

39

Ann Emerg Med. 1990;19(6):677-679

Br J Dermatol. 1995;132(2):257-262.

Tidsskr Nor Laegeforen. 2000;120(13):1549-1551.

42 of 54

Our Patient

IP, a 30-year-old Hispanic female, newly diagnosed with methemoglobinemia secondary to dapsone use…

43 of 54

Primary Team’s Assessment and Plan…

Problem #1

Acute hypoxic respiratory failure 🔪 due to dapsone-induced methemoglobinemia

    • Did not treat methemoglobinemia
    • G6PD deficiency checked prior to starting dapsone: normal
    • Stopped dapsone and switched to atovaquone
    • After stopping dapsone, air requirement decreased from 6L nasal canula to room air

I agree with not treating methemoglobinemia:

No methylene blue 🔪 G6PD deficiency and MetHb < 30%

No ascorbic acid 🔪 improved after discontinuation of dapsone & no severe symptoms

No cimetidine 🔪 dapsone discontinued to alternative therapy

41

    • Rechecked MetHb prior to discharge, MetHb = 8.6% (admission 21.1%)

44 of 54

Primary Team’s Assessment and Plan…

Problem #1

Acute hypoxic respiratory failure 🔪 due to dapsone-induced methemoglobinemia

    • Did not treat methemoglobinemia
    • G6PD deficiency checked prior to starting dapsone: normal
    • Stopped dapsone and switched to atovaquone
    • After stopping dapsone, air requirement decreased from 6L nasal canula to room air

I agree with not treating methemoglobinemia:

No methylene blue 🔪 G6PD deficiency and MetHb < 30%

No ascorbic acid 🔪 improved after discontinuation of dapsone & no severe symptoms

No cimetidine 🔪 dapsone discontinued to alternative therapy

41

    • Rechecked MetHb prior to discharge, MetHb = 8.6% (admission 21.1%)

One recommendation I would have made,

would be to consider genetic testing

45 of 54

Primary Team’s Assessment and Plan…

Problem #2:

Dapsone-induced hemolysis from oxidative stress

    • Indicated by bite and blister cells on the peripheral smear 🔪 dapsone likely the culprit
    • Stopped dapsone and switched to atovaquone 1500 mg daily for PJP ppx

42

46 of 54

Primary Team’s Assessment and Plan…

Problem #3

Acute on chronic anemia of chronic disease (CKD)

    • likely hemolytic 2/2 dapsone plus underlying anemia of chronic disease

I agree:

No G6PD deficiency

Hemolyzed with signs of oxidant stress as seen on peripheral smear w/ bite cells and blister cells

43

47 of 54

Primary Team’s Assessment and Plan…

Problem #3

Acute on chronic anemia of chronic disease (CKD)

    • likely hemolytic 2/2 dapsone plus underlying anemia of chronic disease
    • Received darbepoetin x 2 doses (on 11/1 and 11/2), Hgb was nadired at 4.7 at discharge

I agree:

Jehovah's witness, refused blood transfusion

Iron stores were repleated and normal

Met restriction criteria, CKD – no dialysis w/ Hgb < 10 to be initiated on darbepoetin

43

48 of 54

Primary Team’s Assessment and Plan…

Problem #3

Acute on chronic anemia of chronic disease (CKD)

    • likely hemolytic 2/2 dapsone plus underlying anemia of chronic disease
    • Received darbepoetin x 2 doses (on 11/1 and 11/2), Hgb was nadired at 4.7 at discharge
    • Continued holding antimetabolite and increased prednisone given severe anemia

Unlikely cause of anemia:

If only reason for holding was due to anemia concern, insinuating cause (dapsone) is gone & pt

received ESA

But also, okay to continue holding, with close follow-up outpatient to check Hgb trend and if pt

remained clinically stable

43

49 of 54

Primary Team’s Assessment and Plan…

Problem #3

Acute on chronic anemia of chronic disease (CKD)

    • likely hemolytic 2/2 dapsone plus underlying anemia of chronic disease
    • Received darbepoetin x 2 doses (on 11/1 and 11/2), Hgb was nadired at 4.7 at discharge
    • Continued holding antimetabolite and increased prednisone given severe anemia
    • Discharged with ARC follow-up in 2 weeks for repat CBC and renal labs and further follow up in 6 weeks

I agree:

No need to keep admitted, oxidant stress hemolysis typically takes 2-3 wks to resolve

43

50 of 54

Primary Team’s Assessment and Plan…

Problem #4 (and chief complaint upon admission)

Severe diarrhea

    • C. diff and CMV PCR: negative
    • Held MMF with improvement in diarrhea while admitted, restarted upon discharge
    • Continued prednisone 60 mg daily (f/up with renal for possible taper)

44

51 of 54

Patient Update as of 2/21/22:

  • Anemia improved, Hgb:
    • 8.0 = 11/17
    • 11.1 = 12/14
    • 9.2 = 1/18
  • Darbepoetin filled 1x on 11/5/21, outpatient
  • Dapsone allergy added to chart
    • Not restarted on dapsone
  • No re-hospitalizations ☺
  • Original CC of diarrhea: still reported severe diarrhea despite taking Imodium post-dispo
    • recently switched to Cytoxan 🔪 no diarrhea

​

45

52 of 54

Questions?

Hope Vertrice Askew, PharmD

PGY-1 Pharmacy Resident

Parkland Health

hope.askew.pharm@gmail.com

​

​

​

Thank you to the content expert and style advisor:

Dr. Eileen Marley, PharmD, BCOP

Dr. Taylor Epperson, PharmD, BCPS

CREDITS: This presentation template was created by Slidesgo, including icons by Flaticon, infographics & images by Freepik and illustrations by Stories

53 of 54

References

  • The effect of methemoglobin on the equilibrium between oxygen and hemoglobin Darling R, Roughton F Am J Physiol. 1942;137:56. Prchal JT. Methemoglobinemia and other dyshemoglobinemias. Chap 51. In: Williams Hematology, 10th ed, Kaushansky K, Litchtman MA, Prchal JT, et al (Eds), McGraw Hill, New York 2021. p.859.
  • Mansouri A, Lurie AA. Concise review: methemoglobinemia.Ā Am J Hematol. 1993;42(1):7-12. doi:10.1002/ajh.2830420104
  • Prchal JT.Ā Methemoglobinemia and Other Dyshemoglobinemias.Ā In:Ā Kaushansky K, Prchal JT, Burns LJ, Lichtman MA, Levi M, Linch DC.Ā eds.Ā Williams Hematology, 10e. McGraw Hill; 2021.
  • Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals.Ā Medicine (Baltimore). 2004;83(5):265-273. doi:10.1097/01.md.0000141096.00377.3f
  • Cohen RJ, Sachs JR, Wicker DJ, Conrad ME. Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam.Ā N Engl J Med. 1968;279(21):1127-1131. doi:10.1056/NEJM196811212792102
  • Kane GC, Hoehn SM, Behrenbeck TR, Mulvagh SL. Benzocaine-induced methemoglobinemia based on the Mayo Clinic experience from 28 478 transesophageal echocardiograms: incidence, outcomes, and predisposing factors. Arch Intern Med. 2007;167(18):1977-1982. doi:10.1001/archinte.167.18.1977
  • Bizzarro M, Gross I, Barbosa FT. Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease.Ā Cochrane Database Syst Rev. 2014;(7):CD005055. Published 2014 Jul 3. doi:10.1002/14651858.CD005055.pub3
  • Tejesh C, Shivanna S, Manjunath A, Prathima P. ICU management of Methemoglobinemia due to unknown compound poisoning.Ā J Anaesthesiol Clin Pharmacol. 2013;29(1):139-140. doi:10.4103/0970-9185.105835
  • Patnaik S, Natarajan MM, James EJ, Ebenezer K. Methylene blue unresponsive methemoglobinemia.Ā Indian J Crit Care Med. 2014;18(4):253-255. doi:10.4103/0972-5229.130582
  • Su YF, Lu LH, Hsu TH, Chang SL, Lin RT. Successful treatment of methemoglobinemia in an elderly couple with severe cyanosis: two case reports.Ā J Med Case Rep. 2012;6:290. Published 2012 Sep 11. doi:10.1186/1752-1947-6-290
  • Solheim L, Brun AC, Greibrokk TS, Jacobsen D, Fossum C. Methemoglobinemi--Ć„rsaker, diagnostikk og behandling [Methemoglobinemia--causes, diagnosis and treatment].Ā Tidsskr Nor Laegeforen. 2000;120(13):1549-1551.
  • Coleman MD, Rhodes LE, Scott AK, et al. The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients.Ā Br J Clin Pharmacol. 1992;34(3):244-249. doi:10.1111/j.1365-2125.1992.tb04131.x
  • Rosen PJ, Johnson C, McGehee WG, Beutler E. Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency.Ā Ann Intern Med. 1971;75(1):83-86. doi:10.7326/0003-4819-75-1-83
  • Kearney TE, Manoguerra AS, Dunford JV Jr. Chemically induced methemoglobinemia from aniline poisoning. West J Med. 1984;140(2):282-286.
  • Park SY, Lee KW, Kang TS. High-dose vitamin C management in dapsone-induced methemoglobinemia.Ā Am J Emerg Med. 2014;32(6):684.e1-684.e6843. doi:10.1016/j.ajem.2013.11.036
  • UpToDate. www.uptodate.com. https://www.uptodate.com/contents/methemoglobinemia?search=methemoglobinemia%20adult&source=search_result&selectedTitle=1~150& usage_type=default&display_rank=1#H2334794110
  • DiSanto AR and Wagner JG, ā€œPharmacokinetics of Highly Ionized Drugs II: Methylene Blue - Absorption, Metabolism, and Excretion in Man and Dog After Oral Administration,ā€ J Pharm Sci, 1972, 61(7):1086-90
  • Methylene Blue [prescribing information]. Lake Forest, IL: Akorn Inc; July 2016
  • Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jirovecii pneumonia. Infect Dis Clin North Am. 2010;24(1):107-138. doi:10.1016/j.idc.2009.10.010
  • 2022 UpToDate, Inc. and/or its affiliates. Oxyhemoglobin dissociation curve. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com
  • Pathania V, Shankar P, Sinha P, Tripathy D M. A curious case of palpitation in a leprosy patient with low grade methemoglobinemia. Indian J Drugs Dermatol 2018;4:79-81

47

54 of 54

Treatment Summary

  • For severe methemoglobinemia who require treatment, MB is preferred (when not contraindicated) due to rapid and complete reversal of methemoglobinemia
    • MB can cause severe hemolysis in individuals with G6PD deficiency or life-threatening serotonin syndrome in individuals taking an SSRI or other serotonergic agent 🔪 ascorbic acid is used in these cases
  • Symptoms of methemoglobinemia may be nonspecific (headache, lethargy, irritability); But at higher levels: cyanosis, respiratory failure, neurologic changes (seizures, coma) may occur
  • Individuals where G6PD status is unknown may be treated cautiously with MB instead of ascorbic acid
  • Improvement is assessed clinically. Routine laboratory monitoring is not used because MB interferes with methemoglobin measurements.

www.uptodate.com. Methemoglobinemia.

48